Prescribing patterns of new oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: A narrative review

O.  Chernatska

doi:10.31450/ukrjnd.4(80).2023.10

O. Chernatska Sumy State University

DOI: https://doi.org/10.31450/ukrjnd.4(80).2023.10

Keywords: atrial fibrillation, new oral anticoagulants, creatinine clearance, chronic kidney disease.

Abstract

This study aimed to investigate the prescribing patterns of new oral anticoagulants in atrial fibrillation patients based on creatinine clearance. A thorough analysis of articles published between 2017 and 2021 in databases such as PubMed, Scopus, and Google Scholar was conducted.

The review revealed distinctive features in the use of new oral anticoagulants concerning glomerular filtration rate. Apixaban was identified as a judicious choice for individuals with kidney disorders, with approximately 25% of its dose excreted in urine. American guidelines specifically recommend apixaban for those with a creatinine clearance of less than 15 mL/min, while European recommendations contraindicate all new oral anticoagulants for such rates.

In instances where the glomerular filtration rate ranges from 15 to 29 mL/min, apixaban or edoxaban may be preferred due to the substantial renal elimination of edoxaban. Reduced dose regimens of rivaroxaban, edoxaban, and apixaban are advised for individuals with chronic kidney disease and a creatinine clearance between 15 and 30 mL/min.

Dabigatran, characterized by an 80% renal elimination rate, is recommended for individuals with a creatinine clearance exceeding 30 ml/min according to European guidelines and those with a clearance of at least 15 ml/min according to American guidelines.

Downloads

Download data is not yet available.

References

Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstro¨m-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021 Feb 1;42(5):373-498. doi:10.1093/eurheartj/ehaa612.

Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513-1524. doi:10.1056/nejmoa1708454.

Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509-1524. doi:10.1056/NEJMoa1817083.

Bellin A, Berto P, Themistoclakis S, Chandak A, Giusti P, Cavalli G, et al. New oral anti-coagulants versus vitamin K antagonists in high thromboembolic risk patients. PLoS One. 2019 Oct 7;14(10):e0222762. doi:10.1371/journal.pone.0222762.

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart. 2021; 42(36):3599–3726. doi:10.1093/eurheartj/ehab368.

Stepanova N. Oxalate Homeostasis in Non-Stone-Forming Chronic Kidney Disease: A Review of Key Findings and Perspectives. Biomedicines. 2023;11(6): 1654. doi:3390/biomedicines11061654.

Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010;138:1093-1100. doi:1378/chest.10-0134.

Kovesdy CP. Epidemiology of Chronic Kidney Disease: An Update. Kidney Int. Suppl. 2022;12:7–11. doi:1016/j.kisu.2021.11.003.

Carney EF. The Impact of Chronic Kidney Disease on Global Health. Nat Rev Nephrol. 2020;16:251. doi:1038/s41581-020-0268-7.

Stepanova N. The Gut-Peritoneum Axis in Peritoneal Dialysis and Peritoneal Fibrosis. Kidney Med. 2023 Apr 20;5(6):100645. doi:10.1016/j.xkme.2023.100645.

Stepanova N, Kolesnyk M, Mithani Z, Alkofair B, Shakour RL, Petrova A, et al. Lifesaving Care for Patients with Kidney Failure during the War in Ukraine 2022. Clin J Am Soc Nephrol. 2022 Jul;17(7):1079-1081.doi:10.2215/CJN.04720422.

Yarmolenko O, Bumeister V, Polak S, Gordienko O, Prykhodko O, Demikhova N, et al. The effect of the experimental chronic hyperglycemia on the kidney and myocardium. Ukrainian Journal of Nephrology and Dialysis. 2021;(3):3-10. doi:10.31450/ukrjnd.3(71).2021.01.

Demikhova N, Chernatska O, Mazur T, Bokova S, Rudenko T, Bumeister L, et al. Markers of cardiovascular complications in patients with type 2 diabetes mellitus and arterial h Bangladesh Journal of Medical Science. 2018;17(2):319–322. doi:10.3329/bjms.v17i2.35894.

Marushchak M, Krynytska I, Lepyavko A. Association of serum uric acid with albuminuria in type 2 diabetic patients with comorbid obesity and/or essential arterial hypertension. Ukrainian Journal of Nephrology and Dialysis. 2022;1:58–69. doi;10.31450/ukrjnd.1(73).2022.07.